Search

Vidyalakshmi Chandramohan

from Durham, NC
Age ~47
Get Report
Also known as:
Vidya Chandramohan, Vidyalakshm Chandramohan
Phone and address:
110 Token House Rd, Durham, NC 27703
Connected to:
Abhijith Chandrashekar, 36Abhishek R Chandra, 39Adeesh Chandra, 49Akhileshwari N Chandra, 88Anand B Chandrasekhara, 50Angel A Chandra, 28Anirudh V Chandra, 34Anish Chandra, 52Anitha Chandran, 51Anjana V Chandran, 36

Vidyalakshmi Chandramohan Phones & Addresses

  • 110 Token House Rd, Durham, NC 27703
  • 40 Colborne Rd, Brighton, MA 02135
  • 220 Kelton St, Allston, MA 02134 (617) 713-3763

Publications

Us Patents

Anti-Podoplanin Antibodies And Methods Of Use

View page
US Patent:
20140017266, Jan 16, 2014
Filed:
Dec 5, 2011
Appl. No.:
13/991308
Inventors:
Darell Bigner - Mebane NC, US
Chien-Tsun Kuan - Cary NC, US
Ira H. Pastan - Potomac MD, US
Vidyalakshmi Chandramohan - Durham NC, US
Assignee:
THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HHS, NIH - ROCKVILLE MD
DUKE UNIVERSITY - DURHAM NC
International Classification:
C07K 16/18
C07K 14/21
US Classification:
4241831, 5303917, 536 2353, 435 696, 435375
Abstract:
Recombinant scFv-immunotoxins target tumor cells expressing human podoplanin but not podoplanin-negative or normal cells. The immunotoxins can be used for treatment of malignant glioma patients or any malignant tumor expressing podoplanin. One such immunotoxin comprises a modified exotoxin (PE38) attached to the scFv antibody fragment. This immunotoxin can be used as a therapeutic drug for the treatment of malignant gliomas and other cancers.

Detection Of Cd-155, The Poliovirus Receptor

View page
US Patent:
20210311063, Oct 7, 2021
Filed:
Oct 2, 2017
Appl. No.:
16/340026
Inventors:
- Durham NC, US
Vidyalakshmi Chandramohan - Durham NC, US
Matthias Gromeier - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
G01N 33/574
C07K 16/28
G01N 33/58
G01N 33/60
Abstract:
A reliable assay to specifically detect CD155 in tissue sections has widespread use because CD155 is expressed widely among tumor types. Additionally, detected expression of CD 155 in glioblastoma cells is at levels commensurate with susceptibility to PVSRIPO (a poliovirus construct) infection and killing. An anti-CD155 antibody can achieve mono-specific detection of CD155 in immunoblots of tumor homogenates and immunohistochemistry of tumor formalin fixed, paraffin embedded sections. The assay can be used to determine appropriate use of PVSRIPO in oncolytic immunotherapy against cancers.

Neoadjuvant Cancer Treatment With Immunotoxin And Checkpoint Inhibitor Combination

View page
US Patent:
20210214442, Jul 15, 2021
Filed:
May 16, 2019
Appl. No.:
17/055639
Inventors:
- Durham NC, US
Smita NAIR - Cary NC, US
Vidyalakshmi CHANDRAMOHAN - Durham NC, US
Assignee:
DUKE UNIVERSITY - Durham NC
International Classification:
C07K 16/28
C07K 16/24
A61P 35/00
Abstract:
Provided is a method of treating a tumor in an individual by neoadjuvant therapy, wherein the individual has not previously undergone a resection of the tumor, the method comprising administering an immunotoxin alone or an immune checkpoint inhibitor and an immunotoxin, such as D2C7-immunotoxin (D2C7-IT), followed by resection of the tumor. The method may further comprise administration of immune checkpoint inhibitor following resection.

Combination Treatment

View page
US Patent:
20200368300, Nov 26, 2020
Filed:
Aug 11, 2020
Appl. No.:
16/990036
Inventors:
- Durham NC, US
Matthias Gromeier - Durham NC, US
Smita Nair - Durham NC, US
Vidyalakshmi Chandramohan - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 35/768
A61K 39/13
A61K 39/395
A61P 35/00
C07K 16/28
C12N 7/00
C12N 15/85
A61K 39/39
A61K 9/127
Abstract:
Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.

Production Of Immunotoxin D2C7 - (Scdsfv) -Pe38Kdel

View page
US Patent:
20200046847, Feb 13, 2020
Filed:
Oct 13, 2017
Appl. No.:
16/342914
Inventors:
- Durham NC, US
Vidyalakshmi Chandramohan - Durham NC, US
Charles Pegram - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 47/68
C07K 16/06
C07K 16/28
Abstract:
D2C7-(scdsFv)-PE38KDEL (D2C7-IT) is a recombinant exotoxin A-based immunotoxin (IT), targeting both wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins overexpressed in glioblastomas. A good laboratory practice (GLP) manufacturing process was developed to produce sufficient material for a Phase I/II clinical trial. D2C7-IT was expressed under the control of the T7 promoter in BLR (λ DE3). D2C7-IT was produced by a 10 L batch fermentation process and was then purified from inclusion bodies using anion exchange, size exclusion, and an endotoxin removal process that achieved a yield of over 300 mg of purified protein.

Combination Treatment

View page
US Patent:
20180296614, Oct 18, 2018
Filed:
Oct 14, 2016
Appl. No.:
15/768147
Inventors:
- Durham NC, US
Matthias Gromeier - Durham NC, US
Smita Nair - Cary NC, US
Vidyalakshmi Chandramohan - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 35/768
A61K 39/13
A61K 9/127
A61K 39/395
C07K 16/28
A61P 35/00
C12N 15/85
Abstract:
Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.

Anti-Podoplanin Antibodies And Methods Of Use

View page
US Patent:
20150368353, Dec 24, 2015
Filed:
Jun 1, 2015
Appl. No.:
14/726959
Inventors:
- Durham NC, US
- Rockville MD, US
Ira H. PASTAN - Potomac MD, US
Vidyalakshmi CHANDRAMOHAN - Durham NC, US
International Classification:
C07K 16/30
C07K 14/21
Abstract:
Recombinant scFv-immunotoxins target tumor cells expressing human podoplanin but not podoplanin-negative or normal cells. The immunotoxins can be used for treatment of malignant glioma patients or any malignant tumor expressing podoplanin. One such immunotoxin comprises a modified exotoxin (PE38) attached to the scFv antibody fragment. This immunotoxin can be used as a therapeutic drug for the treatment of malignant gliomas and other cancers.
Control profile
Vidyalakshmi Chandramohan from Durham, NC, age ~47 Get Report